The new study reported that a two-drug combination slowed progression of A.L.S. paralysis by about six weeks over about six months, approximately 25 percent more than a placebo. “Any kind of slowing of progression for a patient with A.L.S. might be valuable even though it’s not a big effect.”He and other experts were careful not to overstate the results and noted that the drug wasn’t shown to improve patients’ condition or halt decline. Still, doctors and advocates said the relentlessness of the illness and the availability of only two approved A.L.S.

Source: New York Times September 02, 2020 21:00 UTC